Abstract
1008Background: In LOTUS (NCT02162719), adding the oral AKT inhibitor IPAT to first-line PAC for mTNBC improved progression-free survival (PFS; primary endpoint) [Kim, Lancet Oncol 2017]. The strat...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have